VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
-0.88%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$227M
AUM Growth
-$15.9M
(-6.5%)
Cap. Flow
-$6.79M
Cap. Flow
% of AUM
-2.99%
Top 10 Holdings %
Top 10 Hldgs %
7.9%
Holding
407
New
8
Increased
60
Reduced
329
Closed
10
Top Buys
Top Sells
Sector Composition
| 1 | Healthcare | 25.28% |
| 2 | Real Estate | 19.7% |
| 3 | Energy | 13.28% |
| 4 | Utilities | 12% |
| 5 | Materials | 10.51% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
RDUS
201
DELISTED
Radius Health, Inc.
RDUS
| $302K | 0.13% |
24,375
-2,240
| -8% | -$27.8K |
|
|
BCYC
202
Bicycle Therapeutics
BCYC
$496M
| $297K | 0.13% |
7,130
-379
| -5% | -$15.8K |
|
|
INBX
203
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $290K | 0.13% |
8,695
-458
| -5% | -$15.3K |
|
|
GBT
204
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $289K | 0.13% |
11,358
-1,038
| -8% | -$26.4K |
|
205
Zai Lab
ZLAB
$3.42B
| $284K | 0.13% |
2,692
-245
| -8% | -$25.8K |
|
206
Arcturus Therapeutics
ARCT
$485M
| $283K | 0.12% |
5,913
-316
| -5% | -$15.1K |
|
207
Acadia Pharmaceuticals
ACAD
$4.26B
| $279K | 0.12% |
16,785
-1,545
| -8% | -$25.7K |
|
208
DT Midstream
DTM
$10.7B
| $279K | 0.12% |
+6,030
| New | +$279K |
|
|
SAGE
209
DELISTED
Sage Therapeutics
SAGE
| $278K | 0.12% |
6,280
-573
| -8% | -$25.4K |
|
|
CCXI
210
DELISTED
ChemoCentryx, Inc.
CCXI
| $276K | 0.12% |
16,142
-843
| -5% | -$14.4K |
|
211
Legend Biotech
LEGN
$6.66B
| $266K | 0.12% |
5,265
-266
| -5% | -$13.4K |
|
|
EPZM
212
DELISTED
Epizyme, Inc
EPZM
| $266K | 0.12% |
51,919
-4,755
| -8% | -$24.4K |
|
|
BLUE
213
DELISTED
bluebird bio
BLUE
| $261K | 0.11% |
1,053
-97
| -8% | -$24K |
|
214
ALX Oncology
ALXO
$65.3M
| $260K | 0.11% |
3,526
-192
| -5% | -$14.2K |
|
215
Atara Biotherapeutics
ATRA
$90.7M
| $259K | 0.11% |
580
-30
| -5% | -$13.4K |
|
216
Karyopharm Therapeutics
KPTI
$57.2M
| $258K | 0.11% |
2,958
-271
| -8% | -$23.6K |
|
217
Zentalis Pharmaceuticals
ZNTL
$126M
| $253K | 0.11% |
3,794
-198
| -5% | -$13.2K |
|
218
Ascendis Pharma
ASND
$12.5B
| $252K | 0.11% |
1,581
-83
| -5% | -$13.2K |
|
|
ALLK
219
DELISTED
Allakos
ALLK
| $248K | 0.11% |
2,340
-122
| -5% | -$12.9K |
|
220
IDEAYA Biosciences
IDYA
$2.38B
| $247K | 0.11% |
9,675
-502
| -5% | -$12.8K |
|
221
Kymera Therapeutics
KYMR
$3.11B
| $247K | 0.11% |
4,205
-216
| -5% | -$12.7K |
|
|
ADAP
222
Adaptimmune Therapeutics
ADAP
$10.9M
| $245K | 0.11% |
47,350
-2,469
| -5% | -$12.8K |
|
223
Kodiak Sciences
KOD
$556M
| $240K | 0.11% |
2,498
-138
| -5% | -$13.3K |
|
224
Mirum Pharmaceuticals
MIRM
$3.82B
| $239K | 0.11% |
11,984
-618
| -5% | -$12.3K |
|
225
Regenxbio
RGNX
$490M
| $237K | 0.1% |
5,660
-302
| -5% | -$12.6K |
|